<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02105623</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2013-09</org_study_id>
    <nct_id>NCT02105623</nct_id>
  </id_info>
  <brief_title>EARly Prevention of aTHeroma Progression</brief_title>
  <acronym>EARTH</acronym>
  <official_title>EARly Prevention of aTHeroma Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHEOL WHAN LEE, M.D., Ph.D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare standard therapy (risk factor control, life style&#xD;
      modification) versus standard therapy plus low-dose rosuvastatin therapy (5mg/day) on&#xD;
      progression of coronary atherosclerosis in statin naive individuals who have mild CAD&#xD;
      (nonobstructive coronary atherosclerotic plaques) and normal LDL (low-density lipoprotein)&#xD;
      cholesterol levels(&lt;130mg/dl).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollement, Low Follow-up rate&#xD;
  </why_stopped>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in total atheroma volume(TAV)</measure>
    <time_frame>2 years</time_frame>
    <description>Percent change in total atheroma volume(TAV) at region of interest defined as(TAV at 24 months-TAV at baseline)/(TAV at baseline)x 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PAV(Percent atheroma volume) at region of interest</measure>
    <time_frame>2years</time_frame>
    <description>Change in PAV(Percent atheroma volume) at region of interest(PAV at 24months-PAV at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overall TAV</measure>
    <time_frame>2years</time_frame>
    <description>Sum of TAV in all coronary segments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TAV at region of interest</measure>
    <time_frame>2years</time_frame>
    <description>TAV at 24months-TAV at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overall CAC(coronary artery calcification) score</measure>
    <time_frame>2years</time_frame>
    <description>overall CAC score at 24months-overall CAC score at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of segment of any coronary atherosclerotic plaques</measure>
    <time_frame>2years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in lipid levels</measure>
    <time_frame>2years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risk factor control Diet Exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risk factor control Rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Therapy</intervention_name>
    <description>Risk factor control Diet Exercise for 24months</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Risk factor control rosuvastatin 5mg/day for 24months</description>
    <arm_group_label>Rosuvastatin therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women at least 35 years of age&#xD;
&#xD;
          -  Mild CAD (nonobstructive coronary atherosclerotic plaques, lumen narrowing &lt;50%) and&#xD;
             CAC score &lt;300 in at least one segment of proximal or mid-portion of major epicardial&#xD;
             coronary arteries&#xD;
&#xD;
          -  LDL cholesterol &lt;130mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of stable angina, or acute coronary syndrome&#xD;
&#xD;
          -  History of transient ischemic attack, or stroke&#xD;
&#xD;
          -  Chronic kidney disease (eGFR&lt; 60ml/min)&#xD;
&#xD;
          -  Diabetes mellitus with microvascular complications or insulin therapy&#xD;
&#xD;
          -  Hypertriglyceridemia (triglyceride &gt;500mg/dl)&#xD;
&#xD;
          -  Any statin therapy in the past 4 weeks&#xD;
&#xD;
          -  Planned cardiac surgery or planned major non-cardiac surgery within 6 months.&#xD;
&#xD;
          -  Chronic disease requiring treatment with oral, intravenous, or intra-articular&#xD;
             corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).&#xD;
&#xD;
          -  A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in&#xD;
             the past 3 years or current treatment for the active cancer.&#xD;
&#xD;
          -  Any clinically significant abnormality identified at the screening visit, physical&#xD;
             examination, laboratory tests, or electrocardiogram which, in the judgment of the&#xD;
             Investigator, would preclude safe completion of the study.&#xD;
&#xD;
          -  Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation&#xD;
             (ALT or AST &gt; 3 times upper limit of normal).&#xD;
&#xD;
          -  History of adult asthma manifested by bronchospasm in the past 6 months, or currently&#xD;
             taking regular anti-asthmatic medication(s).&#xD;
&#xD;
          -  Unwillingness or inability to comply with the procedures described in this protocol.&#xD;
&#xD;
          -  Positive pregnancy test (all female subjects of childbearing potential must have a&#xD;
             urine ÃŸ-human chorionic gonadotropin(hCG) pregnancy test performed at Screening and/&#xD;
             or within 7 days prior to randomization) or is known to be pregnant or lactating.&#xD;
&#xD;
          -  Hypersensitivity to Crestor&#xD;
&#xD;
          -  Skeletal muscle disease&#xD;
&#xD;
          -  Combination use with cyclosporine&#xD;
&#xD;
          -  Galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption&#xD;
&#xD;
          -  Combination use of protease inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2014</study_first_posted>
  <last_update_submitted>June 21, 2018</last_update_submitted>
  <last_update_submitted_qc>June 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>CHEOL WHAN LEE, M.D., Ph.D</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Coronary Arteriosclerosis</keyword>
  <keyword>rosuvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is not a publicly funded trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

